BS1_Strong: The variant is present in gnomAD v4.1 at a grpmax filtering allele frequency of 0.0752%, exceeding the ATM VCEP threshold of >0.05% for BS1. The variant has been observed on 90 alleles including one homozygous individual, with highest frequency in the South Asian population (0.091%).¹ BS3_Moderate: Comprehensive functional assessment of all ATM SNVs using prime editing and deep learning (PMID:40580951) classifies p.Glu958Gly as 'Functional' with high confidence. The variant rescues both ATM-specific phosphorylation activity and radiosensitivity, meeting VCEP criteria for BS3_Moderate.² BP2_Strong: c.2873A>G has been observed in cis with a known pathogenic ATM variant (c.5932G>T, p.Glu1978*) on the same allele, corresponding to -4.0 points (BP2_Strong) under the ATM VCEP PM3/BP2 table.³ BP4_Supporting: REVEL score of 0.121 is below the VCEP benign threshold of ≤0.249. BayesDel score of -0.224 is consistent with a benign prediction. SpliceAI predicts no significant splice impact (max delta 0.19).⁴ No pathogenic criteria were met: PVS1 is not applicable (missense variant). PS1 is not met (no same amino acid change classified as pathogenic at codon 958). PS3 is not met (functional studies show normal, not damaging, effect). PM2 is not met (AF=0.00558% exceeds ≤0.001% VCEP threshold). PP3 is not met (REVEL=0.121 below >0.7333 threshold; SpliceAI=0.19 below ≥0.2 threshold).⁵